Revolution Medicines’ daraxonrasib delivered a practice-changing overall survival gain in the Phase 3 RASolute 302 trial for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), with results published in The New England Journal of Medicine and presented at ASCO 2026. In the randomized study of 500 patients, median survival was 13.2 months with daraxonrasib versus 6.7 months with investigator’s-choice chemotherapy. The trial also showed delayed progression: patients on daraxonrasib did not see disease worsen for a median of 7.2 months compared with 3.6 months on chemotherapy. Across the overall population and a high-prevalence subset carrying the most common RAS mutation, efficacy appeared consistent, and the report did not flag major new safety issues relative to expectations for the program. Researchers and independent commentators framed the magnitude of the survival separation as a pivotal checkpoint for a disease where survival after diagnosis is often roughly one year. The results place additional pressure on existing PDAC treatment strategies and raise the likelihood of regulatory and guideline conversations as the field searches for durable systemic options beyond chemotherapy.